VTRSViatris
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for a decline (~−5% a year). Little growth is priced in even as revenue fell 2% a year over three years, potential value, or a value trap.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What VTRS's price assumes
Today's price asks for −4.9% free cash flow growth a year; over the last three years Viatris delivered −3.6%, less than the record.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 11%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.9%
- Growth the price implies
- −4.9%
Growth the price implies · The price pays for −4.9% free cash flow growth a year for a decade; the business has delivered −3.6% a year over the last three.
- Price / book
- 1.26
Price / book · today's price, trailing year to Jun 30, 2026
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 1.26
- EV / EBIToperating margin −0.59%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 2.06
- Free cash flow, trailing twelve months
- $1.95B
- Market capitalisation
- $17.9B
- 3-year revenue growth
- −1.9%
- 3-year free cash flow growth
- −3.6%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry